Financial Performance - Total revenue for Q2 2025 reached $232.1 million, a 31% increase compared to $177.2 million in Q2 2024[7, 40] - Oncology revenue grew by 22% year-over-year, reaching $158.7 million in Q2 2025, up from $130.3 million in Q2 2024[10, 40] - Biopharma & Data revenue experienced a 28% year-over-year growth, totaling $56 million in Q2 2025 compared to $44 million in Q2 2024[7, 29, 40] - Screening revenue for Q2 2025 was $14.8 million[7, 32, 40] - The company is raising revenue guidance for the full year 2025 to $915 million - $925 million, representing a 24%-25% year-over-year growth[48] Oncology Business - Oncology volume grew by 30% year-over-year[10] - Guardant360 Tissue ASP increased to approximately $2,000, achieving the company's 2028 target ahead of schedule[12] - Reveal identified that 63% of patients with detectable ctDNA experienced recurrence within three years, compared to 15% of those without detectable ctDNA[25] Screening Business - Shield's Q2 2025 revenue reached $15 million[32] - Shield volume in Q2 2025 was 16,000[32] - Shield non-GAAP gross margin improved significantly, reaching 48% in Q1 2025 and 18% in Q4 2024, and 2% in Q2 2025[42]

Financial Performance - Total Neurocrine net product sales reached $682 million in Q2 2025, representing a 21% quarter-over-quarter (QoQ) growth and a 17% year-over-year (YoY) growth compared to Q1 2025 and Q2 2024, respectively [11] - INGREZZA net product sales were $624 million in Q2 2025, reflecting a 15% QoQ growth and an 8% YoY growth compared to Q1 2025 and Q2 2024, respectively [11] - CRENESSITY net product sales amounted to $53 million in Q2 2025, including 664 total new patient enrollment forms [11] - The company narrowed INGREZZA net sales guidance for 2025 to $2.50 - $2.55 billion, reflecting double-digit volume growth partially offset by a lower net price due to expanded access [7, 11] - Cash and investments totaled approximately $1.8 billion as of June 30, 2025 [7] Research and Development - The company initiated all Phase 3 registrational programs for osavampator (AMPA PAM) for MDD and NBI-'568 (Selective M4 Agonist) for schizophrenia [11] - A Phase 1 study was initiated for NBIP-'1435, a long-acting CRF-1 receptor antagonist, for the potential treatment of classic CAH [11] - Phase 2 studies are expected to be initiated for NBI-'568 in bipolar mania and NBI-'570 (Selective Dual M1 / M4 Agonist) for schizophrenia [11] - Top-line data is expected to be reported in Q4 2025 for the Phase 3 study of valbenazine for dyskinetic cerebral palsy and the Phase 2 study of NBI-'770 (NMDA NR2B NAM) for the treatment of MDD [11] Pipeline and Portfolio - The company has a pipeline of 12 programs, including the first biologic program NBIP-'1435 [8] - The company expects Phase 1 muscarinic agonist results for NBI-'567 (Selective M1 Agonist), NBI-'569 (Selective M4 Agonist), and NBI-'570 [11]

Financial Performance - Q4FY25 revenue reached $2.6 billion[5], a 30% increase year-over-year[13] and a 14% increase quarter-over-quarter[13] - Non-GAAP EPS for Q4FY25 was $1.66[5], a 22% increase quarter-over-quarter[13] - Non-GAAP gross margin for Q4FY25 was 41.3%[5], a 610 bps increase year-over-year[13] - Cash flow from operations was $746 million[5], a 104% increase year-over-year[13] - Free cash flow was $675 million[5], a 139% increase year-over-year[13] Capital Allocation - Total debt was reduced by $2.6 billion[5] - A new $2.0 billion share repurchase program was authorized, with $149 million of shares repurchased[5] - A cash dividend of $0.10 per share was initiated[5] Business Segments - Cloud revenue accounted for 90% of total revenue in Q4FY25[7] Q1FY26 Guidance (Non-GAAP) - Revenue is expected to be $2.70 billion, with a variance of +/- $100 million[14] - Gross margin is projected to be between 41% and 42%[14] - EPS is expected to be $1.54, with a variance of +/- $0.15[14]

Q2 2025 Financial Performance - Revenue reached $730.6 million, exceeding the guided range of $650 million to $690 million[14] - Non-GAAP EPS was $0.58, surpassing the guided range of $0.49 to $0.55 and marking a quarterly record[13, 14] - Cash flow from operations amounted to $97.8 million, representing 13.4% of revenues[14] - The company holds a cash balance of $448.0 million, with net leverage (net debt divided by the last twelve months of EBITDA) at 1.2x[14] - Free cash flow was $37.6 million, compared to $31.9 million in Q2 2024[19] Q3 2025 Guidance - Expect revenues to be in the range of $690 million to $730 million[14] - Anticipate non-GAAP EPS to be between $0.57 and $0.63[14] End Market Performance (Q2 2025) - Aerospace & Defense accounted for 45% of revenues, showing a year-on-year growth of 21%[15] - Data Center Computing represented 21% of revenues, with a year-on-year growth of 20%[15] - Medical, Industrial & Instrumentation contributed 15% of revenues, experiencing a year-on-year growth of 28%[15] - Networking saw a significant year-on-year growth of 52%, accounting for 8% of revenues[15]

Financial Performance - Confluent's Q2 2025 revenue reached $282.3 million, a 21% year-over-year increase[9,58] - Cloud revenue was $150.5 million, representing a 28% year-over-year growth[9,56] - The company achieved a Non-GAAP operating margin of 6.3%, a 6 percentage point increase year-over-year[9] - Adjusted Free Cash Flow Margin was 3.9%, a 3 percentage point increase year-over-year[9] - Subscription revenue for Q2 2025 was $270.8 million[54,79] Customer Growth and Retention - Net Retention Rate was 114%[9] - The number of customers contributing $100,000 or more in ARR grew by 24% year-over-year[60] - Customers with >= $1M in ARR increased by 10% YoY[60] Market and Strategy - Confluent estimates a total addressable market (TAM) of over $100 billion[46,70] - The company is focused on expanding its Data Streaming Platform (DSP) capabilities[8,21] - Confluent is transitioning to "Act 3," focusing on a complete Data Streaming Platform[8,48] Revenue Mix - In Q2 2025, US revenue accounted for 53% and International revenue accounted for 47% of the total revenue[58] - Confluent Cloud accounted for 50% of the revenue, Confluent Platform accounted for 46% and Services accounted for 4% of the total revenue in Q2 2025[58]

Q2 2025 Financial Results Align Technology, Inc. July 30, 2025 ©2025 Align Technology Inc. All rights reserved. ©2025, Align Technology Inc. All rights reserved. Safe Harbor and Forward-Looking Statements This presentation, including the tables below, contains forward-looking statements, including statements of beliefs and expectations regarding our ability to successfully manage our business and operations, reduce costs, manage investments and pursue our strategic growth drivers, our expectations regarding ...

Financial Performance - Q3'25 GAAP revenue reached $10238 million, a 12% increase compared to Q3'24 [67] - Q3'25 Non-GAAP revenue also reached $10238 million, with a 12% increase or 04% on a constant currency basis [68] - The company's full-year 2025 revenue guidance is between $4081 million and $4091 million, representing a 13% to 15% increase [71] - Non-GAAP diluted EPS for the full year 2025 is projected to be between $423 and $426, a 37% to 44% increase [71] Segment Performance - Diagnostics revenue in Q3'25 was $4489 million, a 09% increase [69] - Breast Health revenue in Q3'25 was $3652 million, a decrease of 58% [69] - GYN Surgical revenue in Q3'25 was $1784 million, a 63% increase [69] - Skeletal Health revenue in Q3'25 was $313 million, a substantial increase of 621% [69] Strategic Positioning - The company's net debt leverage ratio is 06x, with $19 billion in cash and investments as of Q3'25 [59] - The company has deployed over $57 billion since FY20, including $36 billion on share repurchases and $21 billion on M&A [60] - The company aims to continue double-digit non-GAAP EPS growth, driven by mid-single-digit revenue growth, modest operating margin expansion, regular acquisitions, and meaningful buybacks [57]

EXPOSURE MANAGEMENT REDUCING RISK IN A CLOUD-FIRST WORLD Forward-Looking Statements This presentation includes forward-looking statements. All statements contained in this presentation other than statements of historical facts, including statements regarding our future results of operations and financial position, our business strategy and plans and our objectives for future operations, are forward-looking statements. The words "anticipate," believe," "continue," "estimate," "expect," "intend," "may," "will ...

Financial Performance - Total revenue reached $229.6 million, reflecting an 8% year-over-year growth, or 10% on a constant currency basis[10] - Adjusted EBITDA was $92.6 million, an 8% increase year-over-year, with an adjusted EBITDA margin of 40.3%[10] - Adjusted EPS grew by 7% year-over-year to $0.89[10] - Operating cash flow was approximately $86.1 million[9] Segment Performance - Merchant Acquiring revenue increased by 4% year-over-year to $47.3 million, with adjusted EBITDA up 10% to $20.0 million[23, 14] - Payment Services in Puerto Rico and the Caribbean saw a 4% revenue increase to $56.4 million, with adjusted EBITDA up 5% to $33.0 million[25, 14] - Latin America Payments and Solutions experienced a 15% revenue growth to $86.1 million, or 20% on a constant currency basis, with adjusted EBITDA up 33% to $23.3 million[28, 19] - Business Solutions revenue grew by 4% year-over-year to $64.5 million, but adjusted EBITDA decreased by 13% to $26.0 million[30, 14] Liquidity and Capital Allocation - The company returned $6.4 million to shareholders through dividends and executed $3.7 million in share repurchases[11] - Liquidity stood at $484.5 million as of June 30, 2025[11] Outlook - The company projects revenue between $901 million and $909 million, representing a GAAP growth of 6.6% to 7.6%[40] - Adjusted EPS is projected to be between $3.44 and $3.52, reflecting a growth of 4.8% to 7.0%[40]

Financial Highlights - CPKC's Q2 2025 revenues reached $3.7 billion, a 3% increase compared to Q2 2024[17,41] - The operating ratio improved by 110 bps to 63.7%, with the core adjusted operating ratio also improving by 110 bps to 60.7%[17,41] - Diluted earnings per share increased by 37% to $1.33, while core adjusted diluted earnings per share increased by 7% to $1.12[17,41] - Adjusted free cash increased by 15% to $605 million[51] Volume and Revenue Performance - Revenue Ton Miles (RTMs) increased by 7%[17,32] - Carloads increased by 6%[32] - FX-Adjusted revenue in Bulk increased by 6%, Merchandise decreased by 1%, and Intermodal increased by 8%[34] Operating Performance - FRA personal injuries improved by 8% to 0.77 per 200,000 employee-hours[24,81] - FRA train accident frequency deteriorated by 39% to 0.97 per million train-miles[24,81] - Average terminal dwell for Legacy KCS U S improved 42%[27] Outlook - CPKC anticipates a 10-14% core adjusted diluted EPS growth vs 2024[60] - The company expects mid-single digit RTM growth[60] - Capital expenditures are projected at $2.9 billion[60]